Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study()()

BACKGROUND: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy. In this study, we investigated programmed death ligand 1 and other chec...

Descripción completa

Detalles Bibliográficos
Autores principales: Skertich, Nicholas J., Chu, Fei, Tarhoni, Imad AM, Szajek, Stephen, Borgia, Jeffrey A., Madonna, Mary Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346678/
https://www.ncbi.nlm.nih.gov/pubmed/34386763
http://dx.doi.org/10.1016/j.sopen.2021.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346678/
https://www.ncbi.nlm.nih.gov/pubmed/34386763
http://dx.doi.org/10.1016/j.sopen.2021.07.001

Ejemplares similares